Galapagos Investor Relations Material
Latest events
Q1 2025
Galapagos
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Galapagos NV
Access all reports
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises four Phase 2 programs, three Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Key slides for Galapagos NV
Q2 2024
Galapagos NV
Q4 2024
Galapagos NV
Latest articles
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
Ticker symbol
GLPG
Country
🇳🇱 Netherlands